NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

茲卡病毒檢驗的全球市場:各診斷測試的類型,終端用戶,地理的成長率,趨勢及預測(2018年∼2023年)

Zika Virus Testing Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 659355
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
茲卡病毒檢驗的全球市場:各診斷測試的類型,終端用戶,地理的成長率,趨勢及預測(2018年∼2023年) Zika Virus Testing Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

全球茲卡病毒檢驗市場,預計從2018年到2023年的預測期間內,以約5.5%的年複合成長率成長。茲卡病毒屬於福爾馬病毒屬,由埃及斑蚊傳染。市場主要由於研究開發活動的增加和茲卡病毒感染的增加促進成長。各地區中,由於醫療保健基礎設施的整備進行,茲卡病毒的檢驗中幾個生物醫藥品企業技術急速進步,北美主導目前的市場。

本報告提供全球茲卡病毒檢驗市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭
  • 開發平台分析
  • 法規方案

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 市場成長要素
    • 茲卡病毒感染疾病的流行
    • 開發創新試驗的政府積極推動
    • 生物醫藥品企業的研究開發增加
    • 醫療診斷的技術進步
  • 市場阻礙因素
    • 試驗套件的高成本
    • 新興市場上新技術的採用晚
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 診斷試驗的各類型
    • 分子實驗
    • 血清學的檢驗
    • 斑塊減少中和實驗(PRNT)
  • 終端用戶
    • 醫院/診所
    • 研究/診斷研究所
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Abbott
  • Altona Diagnostics GmbH
  • Chembio Diagnostic Systems Inc.
  • ELITechGroup
  • F. Hoffmann-La Roche Ltd
  • Fast Track Diagnostics Ltd
  • Genekam
  • Luminex Corporation
  • Primerdesign Ltd
  • Quest Diagnostics

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 61716

Zika virus (ZIKV) infection has been known to be endemic in Africa and Southeast Asia. The consequent viral spread over the Pacific region led to an outbreak in the developed and emerging countries, worldwide. According to the World Health Organization (WHO), about 84 countries/territories are or have been previously infected by ZIKV transmission. There have been major outbreaks of Zika virus infection in Asia-Pacific (particularly India) and South American countries. As per the Centers for Disease Control and Prevention, Mexico, South America, Central, and Sub-Saharan African countries, and several countries in Southeast Asia are the major countries at risk for the growth of Zika virus infection. Thus, the rising prevalence of Zika virus infection is one of the primary factors driving the growth of the market studied, over the forecast period.

The other prominent drivers of the market studied are increasing R&D by biopharmaceutical companies, and technological advancements in diagnostic tests.

Key Market Trends

Serologic Test Segment is Expected to Show Better Growth in the Forecast Years

The Zika Virus Testing market has been segmented based on test type and end-user. The test type is further segmented into Molecular Test and Serologic Test. The serologic test is expected to grow due to their increased preference as they can detect acute as well as late-stage zika virus infection. In addition, emerging rapid detection serological diagnostics offer shorter turnaround time as well as the differential diagnosis of Zika against other flaviviruses. Furthermore, zika in early pregnancy increases risk of birth defects. According to the CDC, birth defects cases were reported in a higher proportion of babies whose mothers were infected with the zika virus during the first trimester of pregnancy. The virus can be transmitted from an infected pregnant woman to a fetus and causes microcephaly and other severe brain anomalies. This has prompted the testing of pregnant women for the Zika virus, further fueling the growth of the market.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America is expected to dominate the market studied. The growth can be attributed to the rising awareness of the advantages of testing kits. The government organizations, such as the Centers for Disease Control and Prevention (CDC), Pan American Health Organization (PAHO), etc., have been mainly involved in the prevention of Zika virus infection. As per the CDC, About 2 in 20 (10%) babies of women with confirmed Zika virus infection during pregnancy in US states and about 1 in 20 (5%) in US territories had Zika-associated birth defects. The CDC has received funding, to combat the zika outbreak across several territories. In addition, the developed healthcare infrastructure, along with rapid technological advancements by several biopharmaceutical companies in the testing of the zika virus is expected to positively impact the market.

Competitive Landscape

The global players in the Zika Virus Testing market are Abbott Laboratories, Altona Diagnostics GmbH, Chembio Diagnostic Systems Inc., ELITechGroup, F. Hoffmann-La Roche Ltd, Genekam, Luminex Corporation, Novacyt Group, Quest Diagnostics and Siemens AG.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Zika Virus Infection
    • 4.2.2 Increasing R&D by Biopharmaceutical Companies
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Testing Kits
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Molecular Test
    • 5.1.2 Serologic Test
  • 5.2 By End User
    • 5.2.1 Hospital/Clinic
    • 5.2.2 Diagnostics Laboratory
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Altona Diagnostics GmbH
    • 6.1.3 Chembio Diagnostic Systems Inc.
    • 6.1.4 ELITechGroup
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Genekam
    • 6.1.7 Luminex Corporation
    • 6.1.8 Novacyt Group
    • 6.1.9 Quest Diagnostics
    • 6.1.10 Siemens AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS